These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37920257)

  • 1. Classification of HER2-negative breast cancers by
    Loh JW; Lim AH; Chan JY; Yap YS
    Ther Adv Med Oncol; 2023; 15():17588359231206259. PubMed ID: 37920257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
    Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
    BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
    Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
    Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
    Berrino E; Annaratone L; Bellomo SE; Ferrero G; Gagliardi A; Bragoni A; Grassini D; Guarrera S; Parlato C; Casorzo L; Panero M; Sarotto I; Giordano S; Cereda M; Montemurro F; Ponzone R; Crosetto N; Naccarati A; Sapino A; Marchiò C
    Genome Med; 2022 Aug; 14(1):98. PubMed ID: 36038884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
    Venet D; Rediti M; Maetens M; Fumagalli D; Brown DN; Majjaj S; Salgado R; Pusztai L; Harbeck N; El-Abed S; Wang Y; Saura C; Gomez H; Semiglazov VF; de Azambuja E; Huober J; Nuciforo P; Di Cosimo S; Piccart M; Loi S; Rothé F; Sotiriou C
    Clin Cancer Res; 2021 Oct; 27(20):5607-5618. PubMed ID: 34321278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
    Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
    JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome profiling of ERBB2-amplified breast cancers.
    Sircoulomb F; Bekhouche I; Finetti P; Adélaïde J; Ben Hamida A; Bonansea J; Raynaud S; Innocenti C; Charafe-Jauffret E; Tarpin C; Ben Ayed F; Viens P; Jacquemier J; Bertucci F; Birnbaum D; Chaffanet M
    BMC Cancer; 2010 Oct; 10():539. PubMed ID: 20932292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline and Somatic
    Wang X; Kallionpää RA; Gonzales PR; Chitale DA; Tousignant RN; Crowley JP; Chen Z; Yoder SJ; Blakeley JO; Acosta MT; Korf BR; Messiaen LM; Tainsky MA
    Cancer Prev Res (Phila); 2018 Oct; 11(10):655-664. PubMed ID: 30104415
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of
    Lee J; Franovic A; Shiotsu Y; Kim ST; Kim KM; Banks KC; Raymond VM; Lanman RB
    Front Oncol; 2019; 9():212. PubMed ID: 31019892
    [No Abstract]   [Full Text] [Related]  

  • 11. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.
    Chen H; Singh RR; Lu X; Huo L; Yao H; Aldape K; Abraham R; Virani S; Mehrotra M; Mishra BM; Bousamra A; Albarracin C; Wu Y; Roy-Chowdhuri S; Kanagal-Shamanna R; Routbort MJ; Medeiros LJ; Patel KP; Broaddus R; Sahin A; Luthra R
    Oncotarget; 2017 Feb; 8(7):10845-10857. PubMed ID: 28125801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer.
    Liu Q; Huang S; Desautels D; McManus KJ; Murphy L; Hu P
    Comput Struct Biotechnol J; 2023; 21():2940-2949. PubMed ID: 37216014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers.
    Yap YS; Singh AP; Lim JHC; Ahn JH; Jung KH; Kim J; Dent RA; Ng RCH; Kim SB; Chiang DY
    NPJ Breast Cancer; 2018; 4():19. PubMed ID: 30062102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
    Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
    Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
    Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
    Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Role of
    Hwang KT; Kim BH; Oh S; Park SY; Jung J; Kim J; Choi IS; Jeon SY; Kim WY
    J Breast Cancer; 2019 Dec; 22(4):548-561. PubMed ID: 31897329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.
    Gunn S; Yeh IT; Lytvak I; Tirtorahardjo B; Dzidic N; Zadeh S; Kim J; McCaskill C; Lim L; Gorre M; Mohammed M
    BMC Cancer; 2010 Jul; 10():396. PubMed ID: 20667129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.